aTyr Pharma IncNASDAQ:LIFE
- LAST PRICE1.6000
- TODAY'S CHANGE (%)-0.0200 (-1.2346%)
- Bid / Lots1.5700/ 13
- Ask / Lots1.6300/ 10
- Open / Previous Close1.6500 / 1.6200
- Day Range
- 52 Week Range
- Volume159,073
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LIFE |
|---|---|---|
| 09:32 ET | 6180 | 1.62 |
| 09:36 ET | 1400 | 1.615 |
| 09:41 ET | 2000 | 1.615 |
| 09:45 ET | 200 | 1.62 |
| 09:50 ET | 290 | 1.62 |
| 10:03 ET | 100 | 1.625 |
| 10:15 ET | 424 | 1.62 |
| 10:17 ET | 34000 | 1.64 |
| 10:19 ET | 2400 | 1.635 |
| 10:24 ET | 250 | 1.63 |
| 10:26 ET | 500 | 1.63 |
| 10:28 ET | 1439 | 1.6389 |
| 10:30 ET | 2200 | 1.62 |
| 10:32 ET | 920 | 1.62 |
| 10:33 ET | 200 | 1.62 |
| 10:35 ET | 1550 | 1.625 |
| 10:37 ET | 200 | 1.625 |
| 10:39 ET | 100 | 1.625 |
| 10:42 ET | 1600 | 1.62 |
| 10:53 ET | 327 | 1.6298 |
| 11:00 ET | 1823 | 1.6253 |
| 11:02 ET | 350 | 1.625 |
| 11:04 ET | 100 | 1.625 |
| 11:11 ET | 1398 | 1.625 |
| 11:13 ET | 200 | 1.63 |
| 11:15 ET | 200 | 1.625 |
| 11:24 ET | 400 | 1.63 |
| 11:26 ET | 600 | 1.625 |
| 11:29 ET | 3786 | 1.62 |
| 11:31 ET | 500 | 1.615 |
| 11:33 ET | 100 | 1.61 |
| 11:40 ET | 123 | 1.61 |
| 11:44 ET | 350 | 1.615 |
| 11:51 ET | 750 | 1.6101 |
| 11:56 ET | 100 | 1.6125 |
| 12:00 ET | 250 | 1.61 |
| 12:02 ET | 1330 | 1.6107 |
| 12:03 ET | 200 | 1.62 |
| 12:05 ET | 150 | 1.62 |
| 12:12 ET | 380 | 1.615 |
| 12:14 ET | 10300 | 1.615 |
| 12:16 ET | 100 | 1.61 |
| 12:18 ET | 100 | 1.61 |
| 12:20 ET | 2623 | 1.605 |
| 12:21 ET | 200 | 1.605 |
| 12:23 ET | 200 | 1.605 |
| 12:25 ET | 496 | 1.605 |
| 12:27 ET | 100 | 1.605 |
| 12:32 ET | 100 | 1.605 |
| 12:41 ET | 5000 | 1.6005 |
| 12:45 ET | 412 | 1.6 |
| 12:50 ET | 100 | 1.605 |
| 12:52 ET | 200 | 1.605 |
| 12:56 ET | 300 | 1.605 |
| 12:57 ET | 600 | 1.6 |
| 01:01 ET | 100 | 1.605 |
| 01:12 ET | 100 | 1.605 |
| 01:19 ET | 125 | 1.6 |
| 01:26 ET | 200 | 1.605 |
| 01:33 ET | 100 | 1.605 |
| 01:42 ET | 1300 | 1.605 |
| 01:46 ET | 100 | 1.61 |
| 01:50 ET | 100 | 1.6 |
| 01:51 ET | 100 | 1.605 |
| 02:02 ET | 100 | 1.6 |
| 02:08 ET | 21742 | 1.585 |
| 02:11 ET | 100 | 1.585 |
| 02:15 ET | 600 | 1.585 |
| 02:18 ET | 100 | 1.59 |
| 02:20 ET | 1822 | 1.595 |
| 02:24 ET | 625 | 1.5999 |
| 02:26 ET | 100 | 1.6 |
| 02:29 ET | 1054 | 1.595 |
| 02:31 ET | 418 | 1.595 |
| 02:38 ET | 100 | 1.595 |
| 02:40 ET | 2763 | 1.585 |
| 02:42 ET | 100 | 1.585 |
| 02:44 ET | 100 | 1.585 |
| 02:47 ET | 200 | 1.59 |
| 02:49 ET | 1226 | 1.585 |
| 02:58 ET | 100 | 1.59 |
| 03:02 ET | 217 | 1.5811 |
| 03:07 ET | 600 | 1.5817 |
| 03:09 ET | 1488 | 1.59 |
| 03:14 ET | 500 | 1.5899 |
| 03:18 ET | 100 | 1.6 |
| 03:21 ET | 1465 | 1.595 |
| 03:25 ET | 600 | 1.595 |
| 03:32 ET | 100 | 1.595 |
| 03:34 ET | 200 | 1.5999 |
| 03:38 ET | 1000 | 1.595 |
| 03:39 ET | 550 | 1.595 |
| 03:41 ET | 100 | 1.595 |
| 03:43 ET | 100 | 1.595 |
| 03:45 ET | 732 | 1.595 |
| 03:48 ET | 680 | 1.595 |
| 03:50 ET | 200 | 1.595 |
| 03:52 ET | 400 | 1.6 |
| 03:54 ET | 1820 | 1.595 |
| 03:56 ET | 2200 | 1.6 |
| 03:57 ET | 1317 | 1.6 |
| 03:59 ET | 6616 | 1.6 |
Apr 1, 2024
aTyr Pharma to Participate in April Investor Conferences, from 8:00AM ET on Monday Apr 01, 2024 by Dow Jones
8:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
aTyr Pharma Inc | 108.7M | -1.7x | --- |
Eliem Therapeutics Inc | 108.0M | -2.9x | --- |
Genelux Corp | 111.0M | -3.4x | --- |
Leap Therapeutics Inc | 107.1M | -0.5x | --- |
Annovis Bio Inc | 110.8M | -1.6x | --- |
Immunic Inc | 106.1M | -0.6x | --- |
Company Information
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
Contact Information
- Headquarters
- 10240 Sorrento Valley Road, Suite 300SAN DIEGO, CA, United States 92121
- Phone
- 858-731-8389
- Fax
- 858-731-8394
Executives
- Independent Chairman of the Board
- John Clarke
- President, Chief Executive Officer, Director
- Sanjay Shukla
- Chief Financial Officer
- Jill Broadfoot
- General Counsel, Corporate Secretary
- Nancy Denyes
- Independent Director
- Timothy Coughlin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $108.7M |
|---|---|
Revenue (TTM) | $353.0K |
Shares Outstanding | 67.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-0.95 |
Book Value | $1.43 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 307.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15,557.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
